Study of Mindfulness-based Group Treatment in Patients With Depression and Anxiety

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Jan Sundquist, Lund University
ClinicalTrials.gov Identifier:
NCT01476371
First received: November 11, 2011
Last updated: September 25, 2014
Last verified: September 2014

November 11, 2011
September 25, 2014
January 2012
June 2012   (final data collection date for primary outcome measure)
Depression symptoms [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
MADRS-S total score after treatment
Depression symptoms [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
MADRS-S total score after treatment.
Complete list of historical versions of study NCT01476371 on ClinicalTrials.gov Archive Site
  • Depression symptoms [ Time Frame: 1 week after treatment, and 6, 12, and 24 months after completion of the treatment ] [ Designated as safety issue: No ]
    PHQ-9 score after treatment and after 6, 12, and 24 months after completion of treatment
  • Anxiety and depression symptoms [ Time Frame: 1 week after treatment and 6, 12, and 24 months after completion of the treatment ] [ Designated as safety issue: No ]
    HAD score after treatment and after 6, 12, and 24 months
  • Self-rated health [ Time Frame: 8 weeks, 6, 12 and 25 months ] [ Designated as safety issue: No ]
    SCL-90 score after treatment and 6, 12, and 24 months after treatment
  • Systemic inflammation [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    Serum levels of the following inflammatory factors will be measured by enzyme-linked immunosorbent assay (ELISA): epidermal growth factors, adiponectin, high-sensitivity C-reactive protein (hs-CRP), interferon (IFN)-γ, interleukin (IL)-1β, IL-6, IL-10 and tumor necrosis factor (TNF)-α. Serum levels of microRNA and telomere length will be measured by RT-PCR.
  • Depression symptoms [ Time Frame: 1 week after treatment, and 6, 12, and 24 months after completion of the treatment ] [ Designated as safety issue: No ]
    PHQ-9 score after treatment and after 6, 12, and 24 months after completion of treatment
  • Anxiety and depression symptoms [ Time Frame: 1 week after treatment and 6, 12, and 24 months after completion of the treatment ] [ Designated as safety issue: No ]
    HAD score after treatment and after 6, 12, and 24 months
  • Self-rated health [ Time Frame: 8 weeks, 6, 12 and 25 months ] [ Designated as safety issue: No ]
    SCL-90 score after treatment and 6, 12, and 24 months after treatment.
  • Systemic inflammation [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    Serum levels of the following inflammatory factors will be measured by enzyme-linked immunosorbent assay (ELISA): Epidermal growth factors, adiponectin, high-sensitivity C-reactive protein (hs-CRP), interferon (IFN)-γ, interleukin (IL)-1β, IL-6, IL-10 and tumor necrosis factor (TNF)-α. Serum levels of microRNA and telomere length will be measured by RT-PCR.
Not Provided
Not Provided
 
Study of Mindfulness-based Group Treatment in Patients With Depression and Anxiety
Mindfulness-based Group Treatment of Patients With Depression and Anxiety: Effects on Symptoms and Inflammatory Markers in a Randomized Controlled Multicenter Study in Primary Care

The purpose of this study is to determine the effectiveness, with respect to symptoms and systemic inflammatory level, of mindfulness-based group treatment compared with normal treatment in patients diagnosed with minor to moderate mental disorders. The hypothesis is that mindfulness group-treatment 1) will be at least as effective as normal treatment in reducing psychiatric symptoms; 2) will increase quality of life compared with normal treatment; 3) will be costeffective compared with normal treatment; and 4) will reduce inflammation-related markers. The study will be conducted at primary care centers in Skåne, Sweden. We will assess the effect of mindfulness-based group treatment on psychiatric symptoms, quality of life, and health (as rated by the patients themselves) as well as inflammatory markers.

Modern cognitive behavioral therapy (CBT) has since the 1990s involved mindfulness, a meditation-based technique that teaches patients to manage their thoughts and feelings. A problem with individual-based psychotherapies is that they are costly, and therapists educated in mindfulness are scarce. Here, we are seeking basis for healthcare providers in primary care to recommend group-based mindfulness training to patients with minor to moderate mental disorders.

Aims of the study:

The primary aim of this study is to assess the effectiveness of mindfulness-based group treatment of patients with minor to moderate mental disorders in primary care through comparison with patients who receive treatment as usual (controls). The cost-effectiveness of mindfulness-based group treatment as an alternative to individual CBT will also be studied. In addition, since increased systemic inflammation has been linked to mental disorders, the effects of the intervention on systemic inflammation—as measured by serum levels of well-established inflammatory and inflammation-related markers (proteins, miRNAs, SNPs, telomere length)—will also be evaluated. Finally, we intend to analyze gene-environment interactions to see if we can find characteristics in the neighbourhood environment that may predict the development of mental disorders in genetically susceptible individuals.

Parameters evaluated in the study:

Parameters assessed at baseline, before the intervention starts: Blood sampling (level of inflammation and inflammation-related markers); Daily functioning (the Global Assessment of Functioning (GAF) scale); Quality of life (the EQ-5D instrument); Symptom Checklist (SCL-90) instrument; self-rated health (a Swedish Survey of Living Conditions (ULF) question with 5 alternative answers); and mindfulness ability (the Mindfulness Attention Awareness Scale (MAAS)). Post-intervention: Blood sampling, Level of depression (as assessed using the Montgomery-Asberg Depression Rating Scale (MADRS-S); the Patient Health Questionnaire (PHQ-9); Anxiety level and stress reactions (the Hospital Anxiety and Depression (HAD) scale); as well as the above described GAF, EQ-5D, SCL-90, ULF and MAAS. Follow-up: the patients will be assessed by the PHQ-9, HAD, MADRS-S, EQ-5D, GAF, SCL-90, ULF and MAAS questionnaires 6, 12 and 24 months after the end of intervention. As a co-variate to the above described parameters, we will analyze Geographic Information System (GIS)-coordinates for neighbourhood social and physical characteristics.

Study design:

Patients seeking treatment for minor to moderate mental disorders at one of 17 primary care centers in Skåne County, Sweden, and satisfying the inclusion criteria listed below, will be invited to enroll in the study. A total of 30 health care providers (1-2 per primary care center) will be trained as mindfulness instructors. The recruited patients (estimated total 300) will be randomly assigned to one of two groups: the first will receive mindfulness-based group treatment and the second treatment as usual. Patients in both groups will be invited for an initial consultation, during which they will be asked to provide blood samples for analysis of inflammation-related markers, and to complete the questionnaires listed above. Details of the medications the patients are currently taking will be recorded. These consultations will take place before the intervention begins.

The intervention will consist of 8-weeks of mindfulness-based group treatment (one 2-hour session per week; 10 patients per group). Each group session will be led by two mindfulness instructors, who will lead the patients through the Here & Now mindfulness program. Between sessions, patients will perform additional mindfulness practice at home via the Internet. A mindfulness instructor will complete a case report form (CRF) for each patient. This CRF will include records of attendance at the group sessions and details of any medications taken (patients in both the control and intervention groups will be prescribed drugs for their mental disorders as their GPs deem appropriate). The patients will themselves keep a record of the mindfulness practice they perform at home.

Patients in the control group will receive treatment as usual, which may consist of CBT, counseling, or other forms of therapy that are provided in primary care. Full details of the treatment each patient in the control group receives will be recorded in the CRF.

Follow-up will be performed 1 week after the end of the intervention in the intervention group, and after 8 weeks of treatment as usual in the control group. All patients will be asked to fill in the questionnaires listed above and to provide blood samples for analysis of inflammation-related marker levels. Patients will be asked to complete further questionnaires at 6, 12, and 24 months after completion of the intervention.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Mental Disorders
Behavioral: Mindfulness-based group treatment
An 8-week course of mindfulness-based group treatment (one 2-hour session per week; 10 patients per group). Each group session will be led by two mindfulness instructors, who will lead the patients through the Here & Now mindfulness program. Between sessions, patients will perform additional mindfulness practice at home via the Internet.
Other Name: Mindfulness
  • Experimental: Mindfulness-based group treatment
    8 group mindfulness sessions (1 per week), complemented by home mindfulness exercises
    Intervention: Behavioral: Mindfulness-based group treatment
  • No Intervention: Treatment as usual
    Treatment as usual (including individual CBT and medication)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
215
April 2014
June 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Mental disorders: Mild depressive episode (ICD-10 code F32.0)
  • Moderate depressive episode (F32.1)
  • Depressive episode, unspecified (F32.9)
  • Recurrent depressive disorder, current episode mild (F33.0)
  • Recurrent depressive disorder, current episode moderate (F33.1)
  • Panic disorder (F41.0)
  • Generalized Anxiety Disorder (F41.1)
  • Mixed Anxiety and Depression Adjustment (F41.2)
  • Other mixed anxiety disorders (F41.3)
  • Other specified anxiety disorders (F41.8)
  • Anxiety disorders unspecified (F41.9)
  • Adjustment Disorder (F43.2)
  • Other reactions to severe stress (F43.8)
  • Reaction to severe stress, unspecified (F43.9)
  • Age: 20-64 years
  • Ability to speak Swedish
  • Daily access to the Internet
  • Score of ≥10 points on the PHQ-9 OR ≥7 points on the HAD scale OR between 13 and 34 points on the MADRS-S (mild to moderate depression)

Exclusion Criteria:

  • Serious depression/anxiety that needs psychiatric care
  • Personality disorders
  • Suicide risk (score of >4 on item 9 of the MADRS-S)
  • Ongoing treatment at a psychiatric clinic at the time of recruitment
  • Ongoing psychotherapy (e.g., CBT) at the time of recruitment
  • Current alcohol, prescription medicine or narcotic abuse
Both
20 Years to 64 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01476371
CPF-0001
No
Jan Sundquist, Lund University
Lund University
Not Provided
Principal Investigator: Jan Sundquist, M.D., Ph.D. Lund University
Lund University
September 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP